CHRS - Company ID 0001512762
The table below shows Coherus BioSciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$57.89M | -$25.83M | -$46.77M | -$68.73M | -$54.05M | $1.37M |
| Capital expenditure | - | - | - | $152.00K | $615.00K | $145.00K |
| Investing cash flow | $30.66M | -$17.49M | $202.76M | $17.53M | -$35.62M | -$285.48M |
| Dividends paid | - | - | - | - |
Coherus BioSciences, Inc. reported operating cash flow of -$138.51M for fiscal year 2025. That is down 577.7% from -$20.44M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$252.54M (FY 2016) to -$138.51M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $53.59M | -$264.00K | $887.00K | $3.80M | -$1.85M | $2.44M |